AIMS: To evaluate the frequency of somatostatin-receptor 5 (SSTR 5) in pancreatic neuroendocrine tumors by using monoclonal and polyclonal antibodies. MATERIAL AND METHOD: we analyzed 66 proven pancreatic neuroendocrine tumors immunohistochemically with monoclonal (clone UMB-4) and polyclonal SSTR 5-antibodies. Immunoreactive score (IRS) and DAKO-score Her2/neu were evaluated. RESULTS: Immunohistochemistry analysis demonstrated for the IRS a significant higher staining of all specimen using the monoclonal antibodies ( IRS SSTR5 poly vs IRS SSTR 5 mono; 20.0% vs 30.3% p < 0.001) by a correlation of 0.21; p = 0.04. For the HER2 score there was also a significant higher staining in the monoclonal group (Her2 SSTR 5 poly vs Her2 SSTR 5 mono; 21.5% vs 28.8% p < 0.001) by a correlation of 0.20; p = 0.08. CONCLUSION: Both antibodies are useful in staining of SSTR, although UMB-4 demonstrated a 10% higher SSTR 5 staining. Due to the previous underestimated expression rate of SSTR 5, current standards in diagnostics and therapy should be reconsidered. The increasing usage of long-acting pansomatostatin receptor analogues will rise the adverse effects connected to SSTR5 binding.
AIMS: To evaluate the frequency of somatostatin-receptor 5 (SSTR 5) in pancreatic neuroendocrine tumors by using monoclonal and polyclonal antibodies. MATERIAL AND METHOD: we analyzed 66 proven pancreatic neuroendocrine tumors immunohistochemically with monoclonal (clone UMB-4) and polyclonal SSTR 5-antibodies. Immunoreactive score (IRS) and DAKO-score Her2/neu were evaluated. RESULTS: Immunohistochemistry analysis demonstrated for the IRS a significant higher staining of all specimen using the monoclonal antibodies ( IRS SSTR5 poly vs IRS SSTR 5 mono; 20.0% vs 30.3% p < 0.001) by a correlation of 0.21; p = 0.04. For the HER2 score there was also a significant higher staining in the monoclonal group (Her2SSTR 5 poly vs Her2SSTR 5 mono; 21.5% vs 28.8% p < 0.001) by a correlation of 0.20; p = 0.08. CONCLUSION: Both antibodies are useful in staining of SSTR, although UMB-4 demonstrated a 10% higher SSTR 5 staining. Due to the previous underestimated expression rate of SSTR 5, current standards in diagnostics and therapy should be reconsidered. The increasing usage of long-acting pansomatostatin receptor analogues will rise the adverse effects connected to SSTR5 binding.
Authors: Herbert A Schmid; Chiara Lambertini; Harmke H van Vugt; Patrizia Barzaghi-Rinaudo; Judith Schäfer; Rainer Hillenbrand; Andreas W Sailer; Martina Kaufmann; Paolo Nuciforo Journal: Neuroendocrinology Date: 2011-12-13 Impact factor: 4.914
Authors: V Zamora; A Cabanne; R Salanova; C Bestani; E Domenichini; F Marmissolle; N Giacomi; J O'Connor; G Méndez; E Roca Journal: Dig Liver Dis Date: 2009-10-12 Impact factor: 4.088
Authors: Daniel Kaemmerer; Maria Athelogou; Amelie Lupp; Isabell Lenhardt; Stefan Schulz; Peter Luisa; Merten Hommann; Vikas Prasad; Gerd Binnig; Richard Paul Baum Journal: Int J Clin Exp Pathol Date: 2014-07-15
Authors: Guisheng Zhou; Jim Sinnett-Smith; Shi-He Liu; Juehua Yu; James Wu; Robbi Sanchez; Stephen J Pandol; Ravinder Abrol; John Nemunaitis; Enrique Rozengurt; F Charles Brunicardi Journal: Front Physiol Date: 2014-06-25 Impact factor: 4.566
Authors: Shreya Mehta; Philip R de Reuver; Preetjote Gill; Juliana Andrici; Lisa D'Urso; Anubhav Mittal; Nick Pavlakis; Stephen Clarke; Jaswinder S Samra; Anthony J Gill Journal: Medicine (Baltimore) Date: 2015-10 Impact factor: 1.817